Comments
Suven Life Sciences Ltd has secured three product patents for its new chemical entities in Canada, Japan and Korea.
The NCEs are associated with drugs useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention Deficient Hyperactivity Disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia, the Hyderabad-based company said in a release issued here on Tuesday.
The company’s scrip gained 6.5 per cent and is trading at Rs 297.80 on the Bombay Stock Exchange on Tuesday.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.